In TCGA dataset, KRAS‐amplified tumor occupied 8.1% of CIN‐type EGJ adenocarcinoma and 11.3% of CIN‐type gastric adenocarcinoma, which were more frequently observed as compared to the other types of cancers (5.7% in non‐small cell lung adenocarcinoma, 4.4% in pancreatic adenocarcinoma, 3.7% in bladder urothelial carcinoma, 1.9% in uterine corpus endometrial carcinoma, 1.4% in breast invasive carcinoma, 1.0% in colorectal adenocarcinoma, 0.8% in liver hepatocellular carcinoma, and 0.6% in prostate adenocarcinoma).26, 28, 41. The gene discussed is KRAS; the disease is neoplasm.